Lava Therapeutics, a Dutch and U.S. biotech company, has raised $83 million in Series C funding. Novo Ventures and Sanofi Ventures led the round with participation from other investors that included Redmile Biopharma Investments, Ysios Capital, BB Pureos Bioventures, Versant, Gilde Healthcare and MRL Ventures Fund LLC.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: